close

Agreements

1 2 3 4 5 212
Number of results: 4240

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-06-05 Novartis (Switzerland) IBM Watson Health (USA - NY) cognitive solution to provide insights on the expected outcomes of breast cancer treatment options breast cancer collaboration Cancer - Oncology Collaboration agreement
2017-06-02 BMS (USA - NY) Seattle Genetics (USA - WA) Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) relapsed or refractory Hodgkin lymphoma, relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL) clinical research Cancer - Oncology Clinical research agreement
2017-06-02 Innate Pharma (France) Novo Nordisk (Denmark) anti-C5aR (IPH5401) product acquisition Cancer - Oncology Product acquisition
2017-06-01 Inovio Pharmaceuticals (USA - PA) Roche (Switzerland) INO-5401,  INO-9012 and atezolizumab advanced bladder cancer, specifically advanced unresectable or metastatic urothelial carcinoma clinical research Cancer - Oncology Clinical research agreement
2017-05-31 AstraZeneca (UK) nomination Nomination
2017-05-31 Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) binimetinib and encorafenib licensing, development, commercialisation Licensing agreement
2017-05-31 Baxalta (USA - IL) Mayo Clinic (USA - MN) research - R&D Kidney diseases - Renal diseases Research agreement
2017-05-31 Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) binimetinib and encorafenib BRAF-mutant melanoma, BRAF-mutant colorectal cancer licensing - development - commercialisation Cancer - Oncology Licensing agreement
2017-05-30 Array BioPharma (USA - CO) BMS (USA - NY) binimetinib in combination with Opdivo® (nivolumab) and Opdivo® + Yervoy® (ipilimumab) metastatic colorectal cancer in patients with microsatellite stable tumors clinical research Cancer - Oncology Clinical research agreement
2017-05-30 Immunogen (USA - MA) Sanofi (France) isatuximab (SAR650984), SAR566658, SAR408701, additional antibody drug conjugate directed to an undisclosed target, SAR428926 licensing - development - manufacturing - commercialisation Cancer - Oncology Licensing agreement
2017-05-30 Array BioPharma (USA - CO) BMS (USA - NY) binimetinib with Opdivo® (nivolumab) and Opdivo® + Yervoy® (ipilimumab metastatic colorectal cancer in patients with microsatellite stable tumors clinical research Cancer - Oncology Clinical research agreement
2017-05-30 Cambrex (USA - NJ) cGMP facility in Karlskoga (Sweden) opening of new premises Technology - Services Opening of new premises
2017-05-23 Nabriva Therapeutics (Austria) Nabriva Ireland (Ireland) establishment of a new subsidiary in the EU Infectious diseases Establishment of a new subsidiary in the EU
2017-05-23 Immunogen (USA - MA) Debiopharm (Switzerland) IMGN529/DEBIO 1562 B-cell malignancies, such as non-Hodgkin lymphomas product acquisition Cancer - Oncology Product acquisition
2017-05-22 Nektar Therapeutics (USA - CA) Takeda Pharmaceutical (Japan) NKTR-214, with five oncology compounds from Takeda's cancer portfolio lymphoma, melanoma, colorectal cancer R&D - research Cancer - Oncology Research agreement
2017-05-16 Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany) NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab) metastatic pancreatic cancer, metastatic colorectal cancer clinical research Cancer - Oncology Clinical research agreement
2017-05-16 Oryzon Genomics (Spain) nomination Nomination
2017-05-16 Cambrex (USA - NJ) construction of new premises Technology - Services Construction of new premises
2017-05-15 Akebia Therapeutics (USA - MA) Vifor Pharma (Switzerland) Fresenius Medical Care (Germany) vadadustat anemia associated with chronic kidney disease licensing Kidney diseases - Renal diseases Licensing agreement
2017-05-15 CytomX Therapeutics (USA - CA) nomination Cancer - Oncology Nomination